Ozone treatment of nonalcoholic fatty liver:variation of cytokine levels

Fan Xiao-tang; Halida Xiaerfuhazi; Chen Xin-chun; Ma Hai-lin; Shi Xiu-jiang; He Fang-ping

doi:10.3969/j.issn.2095-4344.2015.07.012

Abstract：BACKGROUND:Now, ozone autologous blood reinfusion treatment has been used as a supplementary treatment or auxiliary treatment besides guidelines. But the relevant reports often address the descriptive observation of clinical efficacy, and whether ozone treatment can influence the corresponding serum cytokines is unclear. <br> OBJECTIVE:To observe the effects of ozone autologous blood reinfusion treatment in nonalcoholic fatty liver patients by testing serum nitric oxide, prostaglandin F-2a, interleukin-6, high-sensitive C-reactive protein and oxidized low-density lipoprotein and leptin. <br> METHODS:Thirty-six hospitalized patients with non-alcoholic fatty liver disease were enrol ed, and according to the wishes of the patients, they were divided into ozone treatment group and control group. The control group was only treated by the liver protective drug treatment, and the treatment group was treated with ozone autologous blood reinfusion treatment besides the liver protective drug treatment. Al patients with type 2 diabetes and (or) dyslipidemia received professional hypoglycemic and (or) lipid-lowering therapy. Prostaglandin F-2a, interleukin-6, high-sensitive C-reactive protein, oxidized low-density lipoprotein and leptin levels were compared before and after treatment. <br> RESULTS AND CONCLUSION:Compared with the control group, the serum levels of prostaglandin F-2a and leptin levels were significantly higher in the treatment group (P ≤ 0.05) at baseline, but after treatment, serum leptin levels had no significant difference between the two groups (P>0.05), and serum prostaglandin F-2a levels were stil statistical y different between the two groups (P=0.02). These findings suggest that the ozone autologous blood reinfusion treatment can reduce the serum leptin levels and improve leptin resistance in patients with nonalcoholic fatty liver. Therefore, this treatment may have prevention and treatment effects on the long-term prognosis of nonalcoholic fatty liver disease patients.